Research & Development News Channel

Research reveals widespread use of ineffective COVID-19 treatments after FDA deauthorized their use

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use authorization for two monoclonal antibodies (bamlanivimab/etesevimab and casirivimab/imdevimab) for the treatment of mild to moderate COVID-19 in high-risk, non-hospitalized patients.

Efficacy, cash and more will increase booster shot acceptance

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with cash incentives and if it is made by Moderna or Pfizer.

As the Omicron variant of COVID-19 emerged, Cornell researchers conducted the public opinion survey - thought to be one of the first to assess the factors that affect people's willingness to receive a vaccine booster.

New generation of corona vaccine shows promising results

Researchers at Karolinska Institutet in Sweden are developing a coronavirus vaccine designed to be less sensitive to mutations and equipped for future strains. The vaccine showed promising results in mice in a newly published study in EMBO Molecular Medicine, and the researchers now hope to be able to take it to safety studies on humans.

Study first to link weed killer Roundup® to convulsions in animals

A recent report by the United States Centers for Disease Control and Prevention found more than 80 percent of urine samples from children and adults in the U.S. contained the herbicide glyphosate. A study by Florida Atlantic University and Nova Southeastern University takes this research one step further and is the first to link the use of the herbicide Roundup®, a widely used weed killer, to convulsions in animals.

Metformin drastically reduces COVID hospitalization

The widely available diabetes drug metformin reduced serious outcomes by more than half if started within 4 days of COVID symptoms in a large, randomized, double blind controlled trial, the University of Minnesota announced today. The results were published Aug. 18 in the New England Journal of Medicine.

Powerful new antibody neutralizes all known SARS-CoV-2 variants

As SARS-CoV-2 has evolved and mutated, therapeutic antibodies that worked early in the pandemic have become less effective, and newer variants, especially Omicron, have developed ways to evade the antibodies we make in response to vaccines. A new, broadly neutralizing antibody developed at Boston Children's Hospital could potentially improve our ability to defend against future variants.

Scientists develop gel made from spider silk proteins for biomedical applications

Researchers at Karolinska Institutet in Sweden and the Swedish University of Agricultural Sciences have discovered that spider silk proteins can be fused to biologically active proteins and be converted into a gel at body temperature. One of the goals is to develop an injectable protein solution that forms a gel inside the body, which could be used in tissue engineering and for drug release, but also make gels that can streamline chemical processes where enzymes are used.

Research & Development News

Research reveals widespread use of ineffective COVID-19 treatments after FDA deauthorized their use

Efficacy, cash and more will increase booster shot acceptance

New generation of corona vaccine shows promising results

Study first to link weed killer Roundup® to convulsions in animals

Metformin drastically reduces COVID hospitalization

Powerful new antibody neutralizes all known SARS-CoV-2 variants

Scientists develop gel made from spider silk proteins for biomedical applications

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs